Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMMP Prima BioMed	$1.66 -6.2%	$1.70	$1.32 ▼ $2.72	$243.67M	1.66	159,469 shs	143,868 shs
SCPH scPharmaceuticals	$4.45 -0.2%	$4.55	$1.94 ▼ $6.28	$237.19M	0.4	381,062 shs	233,943 shs
VNRX VolitionRx	$0.66 -1.9%	$0.70	$0.40 ▼ $0.94	$71.03M	1.26	196,966 shs	88,772 shs
VOR Vor Biopharma	$2.20 +7.3%	$1.66	$0.13 ▼ $3.29	$278.70M	2.06	7.95 million shs	6.02 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMMP Prima BioMed	-0.56%	+4.12%	+4.12%	-8.76%	-23.71%
SCPH scPharmaceuticals	-6.69%	-7.08%	-9.72%	+33.53%	-12.81%
VNRX VolitionRx	-1.48%	+8.55%	-0.30%	+31.57%	+11.06%
VOR Vor Biopharma	+0.49%	+23.49%	-7.24%	+1,022.06%	+115.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMMP Prima BioMed	1.1182 of 5 stars	3.5	1.0	0.0	1.1	0.0	0.0
SCPH scPharmaceuticals	4.6227 of 5 stars	3.5	5.0	4.2	3.7	1.7	0.6
VNRX VolitionRx	2.1782 of 5 stars	3.5	0.0	0.0	2.1	2.5	0.0
VOR Vor Biopharma	2.0112 of 5 stars	3.3	0.0	0.0	1.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMMP Prima BioMed	3.00	Buy	$7.00	321.69% Upside
SCPH scPharmaceuticals	3.00	Buy	$14.00	214.61% Upside
VNRX VolitionRx	3.00	Buy	$3.50	430.14% Upside
VOR Vor Biopharma	2.56	Moderate Buy	$6.07	175.76% Upside

Current Analyst Ratings Breakdown

Latest VNRX, VOR, SCPH, and IMMP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
8/14/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
7/17/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMMP Prima BioMed	$5.14M	47.41	N/A	N/A	$1.05 per share	1.58
SCPH scPharmaceuticals	$36.33M	6.53	N/A	N/A	($0.40) per share	-11.13
VNRX VolitionRx	$1.32M	53.84	N/A	N/A	($0.11) per share	-6.00
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/29/2025 (Estimated)
SCPH scPharmaceuticals	-$85.15M	-$1.81	N/A	N/A	N/A	-183.55%	-1,647.86%	-71.76%	N/A
VNRX VolitionRx	-$35.32M	-$0.25	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A
VOR Vor Biopharma	N/A	-$13.66	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest VNRX, VOR, SCPH, and IMMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	SCPH scPharmaceuticals	-$0.30	-$0.34	-$0.04	-$0.34	$15.41 million	$16.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMMP Prima BioMed	N/A	18.86	N/A
SCPH scPharmaceuticals	3.86	3.85	3.14
VNRX VolitionRx	N/A	0.22	0.22
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMMP Prima BioMed	2.32%
SCPH scPharmaceuticals	89.52%
VNRX VolitionRx	8.09%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
IMMP Prima BioMed	3.07%
SCPH scPharmaceuticals	4.78%
VNRX VolitionRx	10.40%
VOR Vor Biopharma	0.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMMP Prima BioMed	2,021	146.79 million	142.28 million	Optionable
SCPH scPharmaceuticals	30	53.30 million	50.75 million	Optionable
VNRX VolitionRx	80	107.60 million	80.80 million	Optionable
VOR Vor Biopharma	140	126.68 million	65.45 million	Not Optionable

VNRX, VOR, SCPH, and IMMP Headlines

Recent News About These Companies

Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 19 at 4:24 AM | finanznachrichten.de

Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright

August 19 at 2:39 AM | marketbeat.com

Vor Biopharma Q3 EPS Forecast Decreased by HC Wainwright

August 19 at 2:16 AM | americanbankingnews.com

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18 at 4:35 PM | globenewswire.com

Analysts Set Expectations for Vor Biopharma FY2028 Earnings

August 17 at 11:31 AM | marketbeat.com

Wedbush Brokers Boost Earnings Estimates for Vor Biopharma

August 17 at 8:27 AM | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Vor Biopharma

August 17 at 3:19 AM | americanbankingnews.com

Vor Biopharma (NYSE:VOR) Given "Buy" Rating at HC Wainwright

August 17 at 2:05 AM | americanbankingnews.com

Vor Biopharma (NYSE:VOR) Receives "Buy" Rating from HC Wainwright

August 16, 2025 | marketbeat.com

Wedbush Comments on Vor Biopharma's Q3 Earnings (NYSE:VOR)

August 16, 2025 | americanbankingnews.com

Vor Biopharma Shares Soar on Positive Results for Autoimmune-Disorder Treatment

August 13, 2025 | marketwatch.com

Vor says drug licensed from RemeGen succeeded in Sjögren’s study

August 13, 2025 | finance.yahoo.com

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

August 13, 2025 | benzinga.com

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

August 13, 2025 | globenewswire.com

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

August 4, 2025 | globenewswire.com

Vor Biopharma (NYSE:VOR) Trading Down 2.9% - Time to Sell?

July 30, 2025 | marketbeat.com

Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 30, 2025 | marketbeat.com

Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board

July 29, 2025 | insidermonkey.com

Vor Biopharma Announces Key Leadership Changes

July 25, 2025 | theglobeandmail.com

Vor Biopharma Inc.'s (NASDAQ:VOR) top holders are insiders and they are likely disappointed by the recent 14% drop

July 23, 2025 | finance.yahoo.com

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

July 21, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VNRX, VOR, SCPH, and IMMP Company Descriptions

Prima BioMed NASDAQ:IMMP

$1.66 -0.11 (-6.21%)

Closing price 04:00 PM Eastern

Extended Trading

$1.66 +0.01 (+0.30%)

As of 05:01 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

scPharmaceuticals NASDAQ:SCPH

$4.45 -0.01 (-0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$4.45 0.00 (0.00%)

As of 04:10 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

VolitionRx NYSE:VNRX

$0.66 -0.01 (-1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$0.68 +0.02 (+2.54%)

As of 04:52 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Vor Biopharma NYSE:VOR

$2.20 +0.15 (+7.32%)

Closing price 04:00 PM Eastern

Extended Trading

$2.17 -0.03 (-1.14%)

As of 05:37 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time